{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stage+2&page=7",
    "query": {
      "intervention": "Stage 2",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 33431,
    "total_pages": 3344,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stage+2&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stage+2&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T22:36:54.728Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06075264",
      "title": "Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vulvar Diseases",
        "HPV Infection",
        "Vulvar HSIL",
        "Pre-Cancerous Dysplasia",
        "HPV Disease",
        "VIN, Usual Type",
        "VIN 2 of Usual Type",
        "VIN 3 of Usual Type",
        "Vin II",
        "Vin III",
        "VIN Grade 2",
        "VIN Grade 3",
        "High Grade Intraepithelial Neoplasia"
      ],
      "interventions": [
        {
          "name": "Artesunate ointment",
          "type": "DRUG"
        },
        {
          "name": "Placebo ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Frantz Viral Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 27,
      "start_date": "2023-12-06",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-10-30T22:36:54.728Z",
      "location_count": 5,
      "location_summary": "Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Mayfield Heights",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06075264"
    },
    {
      "nct_id": "NCT00494663",
      "title": "A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "DIO-902",
          "type": "DRUG"
        },
        {
          "name": "DIO-902 placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "DiObex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 200,
      "start_date": "2007-07",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2008-11-13",
      "last_synced_at": "2026-10-30T22:36:54.728Z",
      "location_count": 12,
      "location_summary": "Muscle Shoals, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 9 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lakewood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00494663"
    },
    {
      "nct_id": "NCT01669187",
      "title": "The Effects of Pre-operative Physical Therapy Education",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Education brochure",
          "type": "OTHER"
        },
        {
          "name": "Live education and exercise instruction",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Oakland University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2011-12",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2014-04-10",
      "last_synced_at": "2026-10-30T22:36:54.728Z",
      "location_count": 2,
      "location_summary": "Saginaw, Michigan",
      "locations": [
        {
          "city": "Saginaw",
          "state": "Michigan"
        },
        {
          "city": "Saginaw",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01669187"
    },
    {
      "nct_id": "NCT06964087",
      "title": "Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type I Diabetes"
      ],
      "interventions": [
        {
          "name": "OPT101",
          "type": "DRUG"
        },
        {
          "name": "OPT101 Placebo to Match (PTM)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Op-T LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 72,
      "start_date": "2026-04-10",
      "completion_date": "2028-08-19",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-10-30T22:36:54.728Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Renton",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06964087"
    },
    {
      "nct_id": "NCT00033293",
      "title": "Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Localized Resectable Neuroblastoma",
        "Localized Unresectable Neuroblastoma",
        "Regional Neuroblastoma",
        "Stage 4 Neuroblastoma",
        "Stage 4S Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Clinical Observation",
          "type": "OTHER"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Immune Globulin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "Up to 8 Years"
      },
      "enrollment_count": 53,
      "start_date": "2004-03-15",
      "completion_date": "2022-12-31",
      "has_results": true,
      "last_update_posted_date": "2023-04-18",
      "last_synced_at": "2026-10-30T22:36:54.728Z",
      "location_count": 97,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 78 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00033293"
    },
    {
      "nct_id": "NCT04663321",
      "title": "Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Treatment Resistant Depression"
      ],
      "interventions": [
        {
          "name": "MK-1942",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 99,
      "start_date": "2021-05-20",
      "completion_date": "2023-09-08",
      "has_results": true,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-30T22:36:54.728Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Colton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04663321"
    },
    {
      "nct_id": "NCT05442216",
      "title": "Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Tagraxofusp",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joshua Zeidner",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2024-05-01",
      "completion_date": "2031-07-21",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-30T22:36:54.728Z",
      "location_count": 7,
      "location_summary": "Miami, Florida • Orlando, Florida • Buffalo, New York + 4 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05442216"
    },
    {
      "nct_id": "NCT00045006",
      "title": "Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-07",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2013-05-30",
      "last_synced_at": "2026-10-30T22:36:54.728Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00045006"
    },
    {
      "nct_id": "NCT01957306",
      "title": "Safety and Efficacy of Dr. Tagliaferri's Menopause Formula",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hot Flashes"
      ],
      "interventions": [
        {
          "name": "Dr. Tagliaferri's Menopause Formula",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Herba Buena, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 65 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2013-11",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-06-13",
      "last_synced_at": "2026-10-30T22:36:54.728Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01957306"
    },
    {
      "nct_id": "NCT03491904",
      "title": "To Assess the Patients' Ability to Self-Administer Fasinumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteoarthritis, Knee",
        "Osteoarthritis, Hip"
      ],
      "interventions": [
        {
          "name": "Fasinumab AI",
          "type": "DRUG"
        },
        {
          "name": "Fasinumab PFS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2019-01-23",
      "completion_date": "2020-12-15",
      "has_results": false,
      "last_update_posted_date": "2021-03-03",
      "last_synced_at": "2026-10-30T22:36:54.728Z",
      "location_count": 23,
      "location_summary": "Gilbert, Arizona • Glendale, Arizona • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03491904"
    }
  ]
}